Xencor, Inc.
NASDAQXNCR carries one of the more stubborn short positions in small-cap biotech into Thursday's Q1 2026 report — and the lending market says the bears have plenty of capacity left to press. Short interest is running at 14.3% of the free float, backed by roughly 10.2 million shares short. That level has been remarkably stable over the past two weeks, barely moving despite an 12% price…
Snapshot as of 22 Jun 2026
XNCR carries one of the more stubborn short positions in small-cap biotech into Thursday's Q1 2026 report — and the lending market says the bears have plenty of capacity left to press. Short interest is running at…
Xencor reports Q1 results after the close on May 6 that land well short of expectations — EPS of -$1.71 against a -$0.75 estimate, with revenues of $4.5M versus the $27.8M the Street had modelled. The Q1 miss arrives…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XNCR — free to start on ORTEX.
Sign up for free →Open XNCR on ORTEX